促性腺激素释放激素激动剂治疗子宫内膜异位症对性激素及骨密度的影响及处理方法

山东大学学报(医学版) ›› 2012, Vol. 50 ›› Issue (3): 83-86.

促性腺激素释放激素激动剂治疗子宫内膜异位症对性激素及骨密度的影响及处理方法

成开花1，张立新2

1. 东南大学医院妇科，南京 210018； 2. 南京明基医院妇产科，南京 210017

收稿日期:2011-11-29 出版日期:2012-03-10 发布日期:2012-03-10
通讯作者: 张立新，女，副主任医师，主要从事妇产科学研究。E-mail：zhanglx123456@163.com
作者简介:成开花（1971- ），女，主治医师，主要从事妇科学研究。

Therapy and effect of GnHRa on sex hormone and bone mineral
density in patients with endometriosis

CHENG Kai-hua1, ZHANG Li-xin2

1.Department of Gynecology, Southeast University Hospital, Nanjing 210018, China;
2. Department of Gynecology and Obstetrics, Nanjing BenQ Hospital, Nanjing 210017, China

Received:2011-11-29 Online:2012-03-10 Published:2012-03-10

摘要/Abstract

摘要：

目的探讨促性腺激素释放激素激动剂（GnRHa）治疗子宫内膜异位症时性激素水平及骨密度水平的变化。方法选择60例子宫内膜异位症患者，分为A、B 2组，各30例，另有30例健康女性为对照组（C组）。A组给予醋酸亮丙瑞林治疗，B组给予醋酸亮丙瑞林联合7甲基异炔诺酮片进行反加治疗，C组不做任何治疗。观察临床疗效，检测治疗后卵泡刺激素（FSH）、黄体生成素（LH）、血清雌二醇（E2）、孕激素（P）以及骨密度水平。结果 A、B 2组临床疗效无统计学差异；A、B 2组治疗4、12周后，FSH、LH、E2、P水平均较治疗前及C组明显下降，差异有统计学意义；治疗4、12周时，B组E2、P水平高于A组，差异有统计学意义；2组治疗后骨密度水平较治疗前无明显下降。结论 GnRHa治疗子宫内膜异位症可使FSH、LH、E2、P水平下降，联合反加疗法可减轻雌激素下降程度，减少骨质流失。

关键词: 促性腺激素释放激素激动剂；子宫内膜异位症；雌激素；骨密度

Abstract:

Objective To investigate the change of sex hormone and bone mineral density (BMD) in patients with endometriosis (EM) using the gonadotropin-releasing hormone agonist (GnHRa). Methods 60 patients with EM were divided into group A (n=30) and group B (n=30)， and 30 healthy female patients were selected as group C. Group A received leuprorelin acetate, group B received leuprorelin acetate combined with 7-tibolone, while group C received nothing. The clinical efficiency, levels of FSH, LH, E2 and P and BMD were observed. Results There was no significant difference in clinical efficiency between group A and group B. The levels of FSH, LH, E2 and P after 4 weeks and 12 weeks in groups A and B more significantly decreased than those before treatment and in group C. The levels of E2 and P in group B were higher than those in group A after 4 weeks and 12 weeks. The levels of BMD in groups A and B did not significantly decrease. Conclusion GnHRa can decrease the levels of FSH, LH, E2 and P，and GnHRa combined with the add-back therapy can release the decreasing extent of sex hormone and reduce the bone loss.

Key words: Gonadotropin-releasing hormone agonist; Endometriosis; Estrogen; Bone mineral density

中图分类号:

R711.71

成开花1，张立新2. 促性腺激素释放激素激动剂治疗子宫内膜异位症对性激素及骨密度的影响及处理方法[J]. 山东大学学报(医学版), 2012, 50(3): 83-86.

CHENG Kai-hua1, ZHANG Li-xin2. Therapy and effect of GnHRa on sex hormone and bone mineral
density in patients with endometriosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 83-86.

参考文献

相关文章 6

[1]	陈岩1，李栋2，张哲1，时庆2，汪大琨2，刘欢2，王国云1. 人脐带间充质干细胞对大鼠子宫内膜异位症病灶神经纤维的影响[J]. 山东大学学报(医学版), 2013, 51(3): 48-51.
[2]	刘静，张辉，颜磊，赵兴波，李明江. RhoE／Rnd3蛋白在子宫腺肌病中的表达及意义[J]. 山东大学学报(医学版), 2012, 50(5): 116-.
[3]	哈春芳 1，2，肖成明1，张晟宁1，刘培淑2. 开放法大鼠子宫内膜异位症模型的建立与评价[J]. 山东大学学报(医学版), 2011, 49(1): 62-66.
[4]	赖晓岚1，华兴2，陈燕辉1. 子宫内膜异位症在位内膜中神经纤维的表达[J]. 山东大学学报(医学版), 2011, 49(1): 107-110.
[5]	张旭艳1,吕秀萍1,李萌萌2,刘华1,李建超3. 来曲唑对大鼠子宫内膜异位症模型VEGF及MVD表达的影响[J]. 山东大学学报(医学版), 2010, 48(5): 58-61.
[6]	. 子宫腺肌病中PTEN和Akt的表达及其相关性研究 [J]. 山东大学学报(医学版), 2009, 47(10): 86-90.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed